本報訊:厘務局發布第062-2025號備忘錄通告,根據食品藥物管理署建議,新增10種治療重大疾病藥物列入免徵增值稅清單。
癌症治療藥物
1. Tegafur + Gimeracil + Oteracil Potassium capsule (20 mg/5.8 mg/19.6 mg)
2. Tegafur + Gimeracil + Oteracil Potassium capsule (25 mg/7.25 mg/24.5 mg)
糖尿病治療藥物
3. Metformin Hydrochloride + Teneligliptin extended-release tablet (as hydrobromide hydrate) (1 g/20 mg)
4. Metformin Hydrochloride + Teneligliptin extended release tablet (as hydrobromide hydrate) (500 mg/20 mg)
高膽固醇治療藥物
5. Atorvastatin (as calcium) + Fenobribrate film-coated tablet (20 mg/160 mg)
高血壓治療藥物
6. Metoprolol tartrate + Ivabradine film-coated tablet (as hydrochloride) (50 mg/5 mg)
7. Metoprolol tartrate + Ivabradine film-coated tablet (as hydrochloride) (25 mg/5 mg)
精神疾病治療藥物
8. Lamotrigine dispersible/chewable tablet (5 mg)
9. Lamotrigine oral dispersible tablet (25 mg)
10. Lamotrigine tablet (25 mg)
厘務局長尊·魯馬義(Jun Lumagui)表示:“此次擴大免稅範圍旨在降低患者治療成本,提升關鍵藥物可及性,此為厘務局優質納稅服務的一環。”